SKIN The Journal of Cutaneous Medicine

Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Christopher EM Griffiths

Page s239

PDF

First "Real-World" Insights on Apremilast Treatment for Patients with Plaque Psoriasis from the LAPIS-PSO Study: An Interim Analysis

Kristian Reich, Stefanie Bomas, Bernhard Korge, Maria Manasterski, Uwe Schwitchtenberg, Hannah Mentz, Kathrin Groegel

Page s15

Poster PDF

Should Package Insert Warnings Deter Prescribing in Psoriasis Patients with Depression?

Graham H Litchman DO, MS, Quinn Thibodeaux, Ryan Rivera-Oyola, John Koo, Rick Fried, Gary Goldenberg, George Han, Sylvia Hsu, Leon Kircik, Melissa Knuckles, Andrea Murina, Jashin Wu, Mark Lebwohl

Page 1-6

PDF

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Evaluation of Creatine Phosphokinase Elevations in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Mark Lebwohl, Bruce Strober, Thomas Scharnitz, Misti Linaberry, Kim Hoyt, Subhashis Banerjee, Renata M. Kisa, George Martin

Page s244

PDF

Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program

Neil J. Korman, Thierry Passeron, Kenneth B. Gordon, Yukari Okubo, Jerry Bagel, Howard Sofen, Richard B. Warren, Neal Bhatia, Lynda Spelman, Kevin Winthrop, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Diamant Thaçi

Page s119

Poster PDF

Deucravacitinib in moderate to severe plaque psoriasis: liver transaminase results from the phase 3 POETYK PSO program

Mark Lebwohl, Alexander Egeberg, Misti Linaberry, Kim Hoyt, Subhashis Banerjee, Renata M. Kisa, Bruce Strober

Page s116

Poster PDF

Apremilast as an Off-Label Therapeutic Agent

Justin W. Marson, Mark Lebwohl

Page 203-227

PDF KOL SUMMARY

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: evaluation of lipid parameters in the phase 3 POETYK PSO-1 and PSO-2 trials

Mark Lebwohl, Bruce Strober, Misti Linaberry, Kim Hoyt, Subhashis Banerjee, Renata M. Kisa, Nehal N. Mehta

Page s115

Poster PDF

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI)

Jeffrey M. Sobell, Boni Elewski, Subhashis Banerjee, Eugene Balagula, Thomas Scharnitz, Victoria Berger, Kim Hoyt, Paul Yamauchi, Miriam Bettencourt, Michael C. Cameron, Mark Lebwohl

Page s238

PDF

Successful Use of Apremilast in Psoriasiform Dermatitis Refractory to Biologics

Christopher Yang, Victor Quan, Ahmad Amin

Page 693-696

PDF

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial

Jerry Bagel, April W. Armstrong, Richard B. Warren, Kim A. Papp, Diamant Thaçi, Alan Menter, Jennifer Cather, Matthias Augustin, Lauren Hippeli, Carolin Daamen, Christopher EM Griffiths

Page s117

Poster PDF

Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

Diamant Thaçi, Mark Lebwohl, Richard B. Warren, Leon Kircik, Subhashis Banerjee, Andrew Napoli, Renata M. Kisa, Misti Linaberry, Kim Hoyt, Andrew Blauvelt

Page s243

PDF

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Melinda Gooderham, Lynda Spelman, Shinichi Imafuku, Marco Romanelli, Joseph F. Merola, April W. Armstrong, Elizabeth Colston, Subhashis Banerjee, Thomas Scharnitz, Andrew Blauvelt

Page s219

Poster PDF

Sustained Improvement in Patient-Reported Outcomes with Continued Apremilast Treatment over 104 Weeks in Patients with Moderate to Severe Psoriasis

M Shane Chapman, Joshua Cirulli, Sandy McBride

Page S23

Poster PDF

Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program

Mark Lebwohl, Richard B. Warren, Howard Sofen, Shinichi Imafuku, Carle Paul, Jacek C. Szepietowski, Lynda Spelman, Thierry Passeron, Elizabeth Colston, Lauren Hippeli, Andrew Napoli, Renata M. Kisa, Subhashis Banerjee, Alan Menter, Diamant Thaçi, Andrew Blauvelt

Page s118

Poster PDF

Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Bruce Strober, Howard Sofen, Shinichi Imafuku, Carle Paul, Melinda Gooderham, Lynda Spelman, Seong Jun Seo, Thierry Passeron, Renata M. Kisa, Victoria Berger, Eleni Vritzali, Kim Hoyt, Matthew J. Colombo, Subhashis Banerjee, Matthias Augustin, Linda Stein Gold, Andrew Alexis, Diamant Thaçi, Andrew Blauvelt, Mark Lebwohl

Page s241

PDF

Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

April W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, Shinichi Imafuku, Mamitaro Ohtsuki, Lynda Spelman, Thierry Passeron, Kim A. Papp, Renata M. Kisa, Victoria Berger, Eleni Vritzali, Kim Hoyt, Matthew J. Colombo, Subhashis Banerjee, Bruce Strober, Diamant Thaçi, Andrew Blauvelt

Page s240

PDF

Efficacy and Safety of Risankizumab Compared with Apremilast in Patients with Moderate Plaque Psoriasis: Mean PASI and BSA Results From the Phase 4 IMMpulse Trial

Linda Stein Gold, Jerry Bagel, Stephen Keith Tyring, Chih-ho Hong, Lev Pavlovsky, Andreas Pinter, Adam Reich, Leonidas Drogaris, Tianshuang Wu, Huzefa Photowala, Vassilis Stakias, Sven Richter, Kim Papp

Page s257

PDF

Efficacy of Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Fixed Combination in the Treatment of Moderate Plaque Psoriasis: Indirect Comparison Between Pooled Phase 3 Trials of HP/TAZ and Oral Treatment (Apremilast)

Brad Glick, Edward Lain, Tina Lin, Robert Israel

Page S30

Poster PDF

Search

Search Results